Compare
West Pharmaceutical Services Inc vs MiniMed Group, Inc. vs Globus Medical Inc vs Dexcom Inc
| Latest fiscal year | West Pharmaceutical Services Inc WST | MiniMed Group, Inc. MMED | Globus Medical Inc GMED | Dexcom Inc DXCM |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2026-04-24 | 2025-12-31 | 2025-12-31 |
| Revenue | $3.07B | $3.10B | $2.94B | $4.66B |
| Revenue growth (YoY) | +6.3% | +14.3% | +16.7% | +15.6% |
| Gross margin | 35.9% | 54.2% | 67.4% (computed) | 60.1% |
| Operating margin | 19.0% | -6.1% | 16.3% | 19.6% |
| Net margin | 16.1% | -10.7% | 18.3% | 17.9% |
| Net income | $493.70M | -$333.00M | $537.87M | $836.30M |
| EPS (Diluted) | $6.79 | -$1.30 | $3.92 | $2.09 |
| Operating cash flow | $754.80M | -$197.00M | $753.45M | $1.44B |
| Free cash flow | $468.90M | -$420.00M | $588.77M | $1.08B |
| Cash & equivalents | $791.30M | $298.00M | $526.16M | $917.70M |
| Total assets | $4.27B | $4.63B | $5.30B | $6.34B |
| Total liabilities | $1.09B | $1.02B | $729.51M | $3.59B |
| Shareholders' equity | $3.18B | $3.61B | $4.57B | $2.75B |
| Return on year-end equity | 15.5% | -9.2% | 11.8% | 30.5% |
| Shares outstanding | 72.00M | 280.82M | n/a | 384.80M |
Revenue, most recent five fiscal years
| Fiscal year | West Pharmaceutical Services Inc | MiniMed Group, Inc. | Globus Medical Inc | Dexcom Inc |
|---|---|---|---|---|
| Latest | $3.07B Ended 2025-12-31 | $3.10B Ended 2026-04-24 | $2.94B Ended 2025-12-31 | $4.66B Ended 2025-12-31 |
| 1 year earlier | $2.89B Ended 2024-12-31 | $2.71B Ended 2025-04-25 | $2.52B Ended 2024-12-31 | $4.03B Ended 2024-12-31 |
| 2 years earlier | $2.95B Ended 2023-12-31 | $2.47B Ended 2024-04-26 | $1.57B Ended 2023-12-31 | $3.62B Ended 2023-12-31 |
| 3 years earlier | $2.89B Ended 2022-12-31 | n/a | $1.02B Ended 2022-12-31 | $2.91B Ended 2022-12-31 |
| 4 years earlier | $2.83B Ended 2021-12-31 | n/a | $958.10M Ended 2021-12-31 | $2.45B Ended 2021-12-31 |